BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11259613)

  • 1. Transcriptional regulation of topoisomerase II alpha at confluence and pharmacological modulation of expression by bis-benzimidazole drugs.
    Tolner B; Hartley JA; Hochhauser D
    Mol Pharmacol; 2001 Apr; 59(4):699-706. PubMed ID: 11259613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells.
    Morgan SE; Beck WT
    Mol Pharmacol; 2001 Feb; 59(2):203-11. PubMed ID: 11160854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of topoisomerase IIalpha expression by a DNA sequence-specific polyamide.
    Hochhauser D; Kotecha M; O'hare C; Morris PJ; Hartley JM; Taherbhai Z; Harris D; Forni C; Mantovani R; Lee M; Hartley JA
    Mol Cancer Ther; 2007 Jan; 6(1):346-54. PubMed ID: 17237293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the human topoisomerase IIalpha gene promoter in confluence-arrested cells.
    Isaacs RJ; Harris AL; Hickson ID
    J Biol Chem; 1996 Jul; 271(28):16741-7. PubMed ID: 8663303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
    Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
    Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-cycle regulation of the DNA topoisomerase IIalpha promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation.
    Adachi N; Nomoto M; Kohno K; Koyama H
    Gene; 2000 Mar; 245(1):49-57. PubMed ID: 10713444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of topoisomerase IIα expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide.
    Pett L; Kiakos K; Satam V; Patil P; Laughlin-Toth S; Gregory M; Bowerman M; Olson K; Savagian M; Lee M; Lee M; Wilson WD; Hochhauser D; Hartley JA
    Biochim Biophys Acta Gene Regul Mech; 2017 May; 1860(5):617-629. PubMed ID: 27750031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells.
    Takano H; Ise T; Nomoto M; Kato K; Murakami T; Ohmori H; Imamura T; Nagatani G; Okamoto T; Ohta R; Furukawa M; Shibao K; Izumi H; Kuwano M; Kohno K
    Anticancer Drug Des; 1999 Apr; 14(2):87-92. PubMed ID: 10405635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase IIalpha gene by heat shock.
    Furukawa M; Uchiumi T; Nomoto M; Takano H; Morimoto RI; Naito S; Kuwano M; Kohno K
    J Biol Chem; 1998 Apr; 273(17):10550-5. PubMed ID: 9553115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular cloning and characterization of the promoter for the Chinese hamster DNA topoisomerase II alpha gene.
    Ng SW; Eder JP; Schnipper LE; Chan VT
    J Biol Chem; 1995 Oct; 270(43):25850-8. PubMed ID: 7592770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression.
    Hopfner R; Mousli M; Jeltsch JM; Voulgaris A; Lutz Y; Marin C; Bellocq JP; Oudet P; Bronner C
    Cancer Res; 2000 Jan; 60(1):121-8. PubMed ID: 10646863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene.
    Asano T; An T; Mayes J; Zwelling LA; Kleinerman ES
    Biochem J; 1996 Oct; 319 ( Pt 1)(Pt 1):307-13. PubMed ID: 8870683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.
    Stacey DW; Hitomi M; Chen G
    Mol Cell Biol; 2000 Dec; 20(24):9127-37. PubMed ID: 11094065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4',6-diamidine-2-phenylindole.
    Woynarowski JM; McHugh M; Sigmund RD; Beerman TA
    Mol Pharmacol; 1989 Feb; 35(2):177-82. PubMed ID: 2465485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ras stimulates DNA topoisomerase II alpha through MEK: a link between oncogenic signaling and a therapeutic target.
    Chen G; Templeton D; Suttle DP; Stacey DW
    Oncogene; 1999 Nov; 18(50):7149-60. PubMed ID: 10597316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the inverted CCAAT box 2 in the topoisomerase IIalpha promoter by JH-37, an imidazole-pyrrole polyamide hairpin: design, synthesis, molecular biology, and biophysical studies.
    Henry JA; Le NM; Nguyen B; Howard CM; Bailey SL; Horick SM; Buchmueller KL; Kotecha M; Hochhauser D; Hartley JA; Wilson WD; Lee M
    Biochemistry; 2004 Sep; 43(38):12249-57. PubMed ID: 15379563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor-Y binding to the topoisomerase IIalpha promoter is inhibited by both the p53 tumor suppressor and anticancer drugs.
    Joshi AA; Wu Z; Reed RF; Suttle DP
    Mol Pharmacol; 2003 Feb; 63(2):359-67. PubMed ID: 12527807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of DNA topoisomerase II in the selective resistance of a mammalian cell mutant to DNA minor groove ligands: ligand-induced DNA-protein crosslinking and responses to topoisomerase poisons.
    Smith PJ; Bell SM; Dee A; Sykes H
    Carcinogenesis; 1990 Apr; 11(4):659-65. PubMed ID: 2157558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor.
    Wang Q; Zambetti GP; Suttle DP
    Mol Cell Biol; 1997 Jan; 17(1):389-97. PubMed ID: 8972219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.